Tianjin Medical Journal

Tianjin Medical Journal ›› 2018, Vol. 46 ›› Issue (10): 1127-1131.doi: 10.11958/20180816

Previous Articles     Next Articles

Research progress of chimeric antigen receptor -T cells in the treatment of multiple myeloma

DONG Qian-qian1＊, WU Wei-wei1＊, ZHANG Xi-you1, CHEN Feng1, 2△, LI Dan-dan1   

  1. 1 Department of Hematology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; 2 Department of Neuro-Oncology, Beijing Tiantan Hospital, Capital Medical University △Corresponding Author E-mail: chenfeng406@sina.com
  • Received:2018-05-23 Revised:2018-08-15 Published:2018-10-15 Online:2018-11-09

PDF (PC)

3840

Abstract: Abstract: Chimeric antigen receptor T cell (Car-T) is a kind of new targeted therapy. With the continuous progress of basic and clinical research, more and more target antigens have been found, making the possible indications for Car-T gradually expanded. Multiple myeloma (MM) is still considered an incurable disease, Car-T immunotherapy based on genetic engineering and targeted therapy is becoming a new approach for treating relapsed and refractory MM. This article briefly reviews the recent progress of this field

Key words: multiple myeloma, receptors, antigen, T-cell, immunotherapy, review